Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939028 · ClinicalTrials.gov registry record · NA
Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery
A NA study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT01939028: Clinical Trial NA study, sponsored by Case Comprehensive Cancer Center.
NCT01939028 is a NA study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01939028, a NA study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
This clinical trial studies lymph node mapping in patients with newly diagnosed endometrial cancer undergoing surgery. Lymph node mapping may help in planning surgery to remove endometrial cancer and affected lymph nodes.
Primary Outcome
Sensitivity estimated as the proportion of true positives among participants with lymph node metastases. Sensitivity Calculation= the number of patients with a positive SLN over those patients with a positive SLN plus those patients with a false negative lymph node.
Interventions
- PROCEDURE therapeutic conventional surgery
- PROCEDURE sentinel lymph node biopsy
- DRUG indocyanine green solution
- DRUG isosulfan blue
- PROCEDURE lymph node mapping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-10 |
| Phase | NA |
Why NCT01939028 stopped before completion
NCT01939028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which therapeutic conventional surgery is the first listed.
NCT01939028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01939028 about?
NCT01939028 is a clinical study titled "Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery". This clinical trial studies lymph node mapping in patients with newly diagnosed endometrial cancer undergoing surgery. Lymph node mapping may help in planning surgery to remove endometrial cancer and affected lymph nodes.
What is the current status of trial NCT01939028?
This trial is currently terminated. It is a NA study. The enrollment target is 58 participants. The study started on 2013-07. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01939028?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), sentinel lymph node biopsy (PROCEDURE), indocyanine green solution (DRUG), isosulfan blue (DRUG), lymph node mapping (PROCEDURE).
Who is sponsoring clinical trial NCT01939028?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01939028's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia